Slides
Page 1
Earnings Presentation Financial Results for Q1 FY2026 August 6 , 2026 FUJIFILM Holdings Corporation Forward - looking statements , such as those relating to earnings forecasts and other projections contained in this material , are management's current assumptions and beliefs based on currently available information . Such forward - looking statements are subject to a number of risks , uncertainties , and other factors . Accordingly , actual results may differ materially from those projected due to various factors . FUJIFILM Value from Innovation
Page 2
FUJIFILM Holdings Corporation 2 Agenda 1 2 3 Earnings Highlights and Key Topics Financial Results and Business Summary by Operating Segment Financial Forecast for FY2026 Consolidated Financial Results for Q1 FY2026 (April to June 2026) FY2026 (Fiscal Year Ending March 2027)
Page 3
FUJIFILM Holdings Corporation 3 Earnings Highlights and Key Topics Q1 FY2026 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices 01
Page 4
FUJIFILM Holdings Corporation Earnings Highlights for Q1 FY2026 〉 Revenue reached a record high for the first quarter Revenue increased, driven by the Healthcare segment with strong endoscope sales, the Electronics segment with solid performance in the Semiconductor Materials and data tapes, as well as favorable exchange rate impacts 〉 Operating income declined as a result of higher fixed costs in the Bio CDMO business, one-time costs aimed at strengthening the organizational structure of the Business Innovation segment, and the impact of rising raw material prices, despite profit growth in the Electronics and Imaging segments Full-year Forecast for FY2026 Revenue Operating income Net income attributable to FUJIFILM Holdings ¥ 826.5 billion ¥ 51.2 billion ¥ 37.4 billion ( +10.3%) （ -32.0%） （ -30.4%） Record high (Exchange rates: ¥159/US$ | +¥14 YoY; ¥185/Euro | +¥21 YoY) Change from previous year Consolidated Performance for Q1 FY2026 Revenue Operating income Net income attributable to FUJIFILM Holdings ¥ 3,560.0 billion ¥ 365.0 billion ¥ 280.0 billion ( +¥90.0 billion) (unchanged) (unchanged) Record high Change from previous forecast (May 12, 2026) Record highRecord high 4 (Exchange rates: Q2-4 ¥155/US$; ¥180/Euro ) (Exchange rates: Full year ¥156/US$; ¥181/Euro ) Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices 〉 Revenue was revised upward, reflecting strong sales in the Electronics segments and others, as well as the impact of foreign exchange rates. Operating income remains the same from the previous forecast (May 12), as profit growth expected in the strong Electronics is offset by factors such as delayed earnings ramp-up in the Bio CDMO business and the impact of rising semiconductor memory prices 〉 Aiming to reach record highs for revenue, operating income, and net income attributable to FUJIFILM Holdings
Page 5
FUJIFILM Holdings Corporation Commencement of Assessment of a Partial Spin-Off of the Business Innovation business as One of the Key Strategic Options Key Topics for Q1 FY2026 Earnings Highlights Q1 FY2025 FY2025 Forecast Appendices Pursuit of the optimal business portfolio ‒ Healthcare and Electronics as high-growth and high- profitability businesses ‒ Imaging with a strong business foundation as a cash- generating business Maintaining financial discipline while implementing growth investments *The timing of the execution of the Spin-off has not been determined; however, the Company will proceed with its assessment, giv ing consideration to executing the Spin-off within the next two to three years. Items to be assessed will include the selection of the listing market for the shares of FUJIFILM Business Innovation Corp. and the possibility of satisfying qualifications for tax -free treatment. The execution of the Spin- off is subject to approvals, certifications and/or permissions by the relevant stock exchange, other relevant authorities, as well as shareholders and other stakeholders. FUJIFILM Holdings Corp. FUJIFILM Business Innovation Corp. Building the optimal business portfolio to achieve sustainable growth Establishing more agile management decisions for the Business Innovation business, with the aim of achieving further growth Healthcare Electronics Imaging Business Innovation Our Shareholders Over 80% Less than 20% Allocating management resources in line with business needs ‒ Strong earnings base and cash generation capability ‒ Further growth and enhancement of corporate value ‒ Transformation into a solutions-oriented business leveraging customer base and technological capabilities Balancing shareholder returns and growth investments backed by robust cash flow 5
Page 6
FUJIFILM Holdings Corporation 6 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices Financial Results and Business Summary by Operating Segment Q1 FY2026 02
Page 7
FUJIFILM Holdings Corporation Financial Results for Q1 FY2026 (April to June 2026) * Excludes the impacts of foreign exchange, one-time costs, raw material costs, and rising semiconductor memory prices. 7 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices Operation* 749.5 826.5 77.0 20.1 100.0% 100.0% +10.3% +2.7% 75.3 51.2 (24.1) (26.2) 10.0% 6.2% (32.0%) (34.8%) 72.0 52.1 (19.9) 9.6% 6.3% (27.6%) 53.8 37.4 (16.3) 7.2% 4.5% (30.4%) ¥145 ¥159 ¥14 ¥164 ¥185 ¥21 (Billions of yen) Revenue Operating Income Exchange ￥/US$ Rates ￥/€ Income before Income Taxes Net Income Attributable to FUJIFILM Holdings EPS (¥13.37) Q1 ¥31.26¥44.63 FY2025 FY2026 Change Record high Despite a year-on-year decline in Q1 earnings, overall performance was largely in line with the Company’s internal plan
Page 8
FUJIFILM Holdings Corporation Consolidated Revenue and Operating Income by Operating Segment Q1 FY2026 (April to June 2026) * Excludes the impacts of foreign exchange, one-time costs, raw material costs, and rising semiconductor memory prices. Includes approximately ¥1.0 billion in profit improvement from U.S. tariff refunds (net of customer rebates and other offsets). 8 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) 228.5 256.8 28.4 +12.4% 10.8 +4.7% 102.1 127.7 25.5 +25.0% 16.5 +16.2% 273.6 273.2 (0.3) (0.1%) (14.1) (5.2%) 145.3 168.8 23.5 +16.2% 6.9 +4.8% 749.5 826.5 77.0 +10.3% 20.1 +2.7% 4.3 (12.7) (17.0) Turned to loss (19.4) Turned to loss 22.5 31.1 8.6 +38.2% 5.2 +23.1% 15.6 (1.4) (17.0) Turned to loss (10.0) Turned to loss 41.8 43.4 1.6 +3.9% (1.7) (4.1%) (8.8) (9.2) (0.4) (0.3) 75.3 51.2 (24.1) (32.0%) (26.2) (34.8%) FY2025 FY2026 Change Operation* Change Constant-currency basis Q1 Q1 Total Corporate Expenses & Eliminations Imaging Electronics Healthcare Business Innovation Operating Income Revenue Imaging Electronics Business Innovation Total Healthcare FY2026FY2025
Page 9
FUJIFILM Holdings Corporation Business Summary: Healthcare Q1 FY2026 (April to June 2026) Medical Systems + Sales of endoscope increased in the U.S. and Europe, as well as in Japan and China. Strong growth continuing from the previous quarter + Sales of medical IT increased Bio CDMO (*Refer to pp. 24-25 for details on profitability) + Revenue from large-scale facilities increased by more than 60%, driven by expanded operations of new large-scale facilities and the rebound from scheduled maintenance in the previous fiscal year − Revenue from small-to medium scale facilities declined due to unplanned shutdowns for regulatory inspections and the absence of cancellation fees recorded in the previous fiscal year LS Solutions + Sales of culture media increased, driven by expanded usage by major pharmaceutical companies One-time factor (Q1 FY2025) Bio CDMO Scheduled maintenance at Denmark facilities Operations + Medical Systems / LS Solutions Increased gross margin driven by revenue growth − Bio CDMO Profit declined due to upfront costs with the start of operations at new large-scale facilities (U.S.) and shutdowns of small- to medium-scale facilities (U.S.) for regulatory inspections Raw materials prices Medical Systems Rising silver prices, etc. One-time factor (Q1 FY2026) Sale of non-core assets Factors affecting revenue Main factors affecting income Operating income analysis Revenue and income *² Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business within the Healthcare segment to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation. *² *² *¹ Excludes the impacts of foreign exchange, one- time costs, raw material costs, and rising semiconductor memory prices. 9 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices （Billions of yen） Operation*¹ 228.5 256.8 28.4 +12.4% +4.7% 144.0 162.4 18.4 +12.8% +5.4% 54.2 57.7 3.5 +6.4% (3.6%) 30.3 36.7 6.5 +21.4% +16.7% 4.3 (12.7) (17.0) Turned to loss Turned to loss 1.9% (4.9%) (6.8pt) Change Revenue Medical Systems Bio CDMO LS Solutions FY2025 FY2026 Operating Income Operating Margin 4.3 12.8 (12.7) 8.5 (7.7) (0.2) FY25 Q1 FY25 Q1 one-time factor FY25 Q1 (excluding one-time factor) (19.4) Operation 1.2 FX Raw material prices Rising semiconductor memory prices 0.7 One-time factor FY26 Q1
Page 10
FUJIFILM Holdings Corporation Business Summary: Electronics Factors affecting revenue Main factors affecting income Semiconductor Materials + Strong sales across all product lines driven by capturing demand for AI semiconductors Sales of copper interconnect CMP slurry and NTI developers, both of which maintain the top global market share, increased significantly Strong sales of liquid-type polyimides for advanced packaging + In addition to strong sales to major foundries, sales to major semiconductor manufacturers in the U.S. and South Korea recovered AF Materials + Data tape: Higher sales to major IT companies driven by increasing demand Operations Higher gross margin driven by increased sales of semiconductor materials and data tape Operating income analysis Revenue and income Q1 FY2026 (April to June 2026) * Excludes the impacts of foreign exchange, one- time costs, raw material costs, and rising semiconductor memory prices. 10 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices （Billions of yen） Operation* 102.1 127.7 25.5 +25.0% +16.2% 64.7 84.9 20.2 +31.3% +19.5% 37.5 42.8 5.3 +14.1% +10.3% 22.5 31.1 8.6 +38.2% +23.1% 22.1% 24.4% +2.3pt FY2026 Change Revenue Semiconductor Materials FY2025 AF Materials Operating Income Operating Margin 5.2 3.8 0.0 FY25 Q1 one-time factor FY25 Q1 (excluding one-time factor) Operation FX (0.4) Raw material prices FY26 Q1One-time factor 0.0 Rising semiconductor memory prices 0.0 22.5 22.5 31.1 FY25 Q1
Page 11
FUJIFILM Holdings Corporation Business Summary: Business Innovation Operating income analysis Revenue and income Business Solutions (BS) + Higher revenue from overseas ERP system sales and implementation support services − Rebound from overseas BPO revenue in the previous fiscal year Office Solutions (OS) − Decline in exports to Europe and the U.S. Promoted market development of own-brand products and new OEM contracts − Decline in replacement demand for devices in China Promoted optimization of direct sales and dealer coverage by region, in addition to shifting sales from low-margin products to high-end models Graphic Communications (GC) + Higher revenue from inkjet printheads − Lower demand for printing plates and related products amid sluggish market conditions in Europe One-time factor (Q1 FY2025) GC and others Disputed costs / others Operations BS Rebound from overseas BPO revenue in the previous fiscal year OS Gross margin declined due to lower revenue and other factors Common Initial and related costs incurred in connection with the ERP system renewal Raw materials prices GC Rising aluminum prices and other factors One-time factor (Q1 FY2026) BS/OS/GC Structure strengthening expenses, etc. Factors affecting revenue Main factors affecting income Q1 FY2026 (April to June 2026) * Excludes the impacts of foreign exchange, one- time costs, raw material costs, and rising semiconductor memory prices. 11 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices （Billions of yen） Operation* 273.6 273.2 (0.3) (0.1%) (5.2%) 75.8 77.8 2.0 +2.7% (1.9%) 120.0 114.5 (5.5) (4.6%) (8.5%) 77.8 81.0 3.2 +4.1% (3.2%) 15.6 (1.4) (17.0) Turned to loss Turned to loss 5.7% (0.5%) (6.2pt) FY2026 Change Revenue Business Solutions FY2025 Office Solutions Graphic Communications Operating Income Operating Margin 15.6 16.0 (1.4) 0.4 0.7 FY25 Q1 FY25 Q1 one-time factor FY25 Q1 (excluding one-time factor) (10.0) Operation FX (2.8) Raw material prices (1.1) Rising semiconductor memory prices (4.2) One-time factor FY26 Q1
Page 12
FUJIFILM Holdings Corporation Business Summary: Imaging Consumer Imaging + Sales of instax instant photo systems remained strong across a broad range of user segments, driven by solid performance of mid- to high-priced products such as instax mini Evo and instax WIDE 400, alongside the April launch of the new entry-level model instax mini 13 + Supply increased following enhancements in instax film production facilities Professional Imaging + Sales of X Series and GFX Series digital cameras remained strong, led by long-selling models such as X100VI, flagship models such as X-T30 III and X-E5, which were newly launched last year Revenue declined excluding foreign exchange impacts, due to a tough comparision with strong sales of two newly launched products in the same period of the previous fiscal year Operations Higher gross margin driven by higher revenue in instax instant photo systems Lower gross margin due to a tough comparision with strong digital camera sales in the same period of the previous fiscal year Raw materials Rising silver prices, etc. One-time factor (Q1 FY2026) Consumer Imaging Structure strengthening expenses Factors affecting revenue Main factors affecting income Operating income analysis Revenue and income Q1 FY2026 (April to June 2026) * Excludes the impacts of foreign exchange, one- time costs, raw material costs, and rising semiconductor memory prices. 12 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices （Billions of yen） Operation*¹ 145.3 168.8 23.5 +16.2% +4.8% 77.3 96.7 19.4 +25.1% +13.1% 68.0 72.1 4.1 +6.0% (4.6%) 41.8 43.4 1.6 +3.9% (4.1%) 28.7% 25.7% (3.0pt) FY2026 Change Revenue Consumer Imaging FY2025 Professional Imaging Operating Income Operating Margin 10.6 Raw material prices (2.4) Rising semiconductor memory prices (2.3) One-time factor FY26 Q1FXOperation (1.7) FY25 Q1 (excluding one-time factor) FY25 Q1 one-time factor 0.0 FY25 Q1 41.8 41.8 43.4 (2.6)
Page 13
FUJIFILM Holdings Corporation Consolidated Cash Flow Cash in Cash out Adjusted free cash flow excluding business acquisitions * Business acquisitions are deducted from adjusted free cash flow. Q1 FY2026 (April to June 2026) 13 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) (Billions of yen) FY2024 3months FY2025 3months FY2026 3months Net income 60.9 53.8 37.6 Depreciation & amortization 39.7 40.9 50.4 Change in notes and accounts receivable / others 52.6 49.8 84.4 Change in inventories (34.5) (52.3) (60.3) Change in notes and accounts payable - trade / others 12.4 (0.5) 5.3 Change in working capital 30.5 (3.0) 29.4 (33.6) 13.0 (41.0) Cash-In 97.4 104.7 76.4 Capital expenditure (118.6) (116.6) (94.0) Purchases of software / rental assets (24.3) (13.8) (17.2) 0.0 (1.2) 0.0 Cash-Out (142.9) (131.6) (111.2) Adjusted free cash flows (FCF) (45.4) (26.9) (34.8) (45.4) (25.7) (34.8)Adjusted free cash flows excluding business acquisitions* Others Acquisitions of businesses 97.4 104.7 76.4 (142.9) (131.6) (111.2) (45.4) (25.7) (34.8) 0.0) 0.0) 0.0 0.0 0.0 FY2024 3months FY2025 3months FY2026 3months
Page 14
FUJIFILM Holdings Corporation 14 Financial Forecast for FY2026 03 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices
Page 15
FUJIFILM Holdings Corporation Full-year Forecast for FY2026 * EPS (net income attributable to FUJIFILM Holdings per share) is calculated by using the number of shares issued as of June 30, 2 026 (excluding treasury shares) as the average number of shares for the relevant period. 15 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) 3,357.0 3,470.0 3,560.0 203.0 90.0 100.0% 100.0% 100.0% +6.0% +2.6% 350.2 365.0 365.0 14.8 - 10.4% 10.5% 10.3% +4.2% - 366.6 375.0 375.0 8.4 - 10.9% 10.8% 10.5% +2.3% - 276.7 280.0 280.0 3.3 - 8.2% 8.1% 7.9% +1.2% - ¥229.65 ¥234.19 ¥234.19 ¥4.54 ‐ 7.7% 7.8% 7.8% 0.1 pt - 5.5% 5.6% 5.6% 0.1 pt - 106 days 101 days 101 days (5 days) - ¥151 ¥150 ¥156 ¥5 ¥6 ¥175 ¥175 ¥181 ¥6 ¥6 ¥247,000 ¥400,000 ¥395,000 ¥148,000 (¥5,000) FY2026 Previous forecast (as of May. 12, 2026) Change from FY2025 Exchange Rates ￥/US$ Change from previous forecast FY2026 Revised forecast (as of Aug. 6, 2026) FY2025 Actual ROIC CCC ￥/€ Silver Price (/kg) Operating Income Revenue Income before Income Taxes Net Income Attributable to FUJIFILM Holdings EPS ROE * Record high Record high Record high Record high
Page 16
FUJIFILM Holdings Corporation Financial Forecast by Operating Segment Operating income was revised downward for Healthcare segment to reflect delayed earnings ramp-up in Bio CDMO business, while it was revised upward for Electronics and Business Innovation segments 16 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices * Excludes the impacts of foreign exchange, one-time costs, raw material costs and rising semiconductor memory prices. Includes approximately ¥6.0 billion in profit improvement from U.S. tariff refunds (net of customer rebates and other offsets). (Billions of yen) 1,098.9 1,170.0 1,180.0 10.0 +0.9% (21.5) (1.8%) 456.2 475.0 510.0 35.0 +7.4% 21.0 +4.4% 1,174.8 1,175.0 1,200.0 25.0 +2.1% (4.0) (0.3%) 627.1 650.0 670.0 20.0 +3.1% (11.0) (1.7%) 3,357.0 3,470.0 3,560.0 90.0 +2.6% (15.5) (0.4%) 63.6 69.0 41.0 (28.0) (40.6%) (30.0) (43.5%) 100.9 106.0 120.0 14.0 +13.2% 8.5 +8.0% 63.7 65.0 80.0 15.0 +23.1% 3.5 +5.4% 160.0 162.0 162.0 - - (4.0) (2.5%) (38.0) (37.0) (38.0) (1.0) - (1.0) ‐ 350.2 365.0 365.0 - - (23.0) (6.3%) FY2026 Previous forecast (as of May. 12, 2026) FY2026 Previous forecast (as of May. 12, 2026) FY2026 Revised forecast (as of Aug. 6, 2026) FY2026 Revised forecast (as of Aug. 6, 2026) Constant-currency basis Operation* Change from previous forecast Change from previous forecast Total Corporate Expenses & Eliminations Total Imaging Business Innovation Operating Income Healthcare Electronics FY2025 Actual Healthcare Revenue FY2025 Actual Imaging Business Innovation Electronics
Page 17
FUJIFILM Holdings Corporation Financial Impact of Rising Semiconductor Memory and IT-related Components Prices Operating income forecast for FY2026 1Q actual Previous (May 12, 2026) Latest (August 6, 2026) Main products affected Total -3.7 billion yen -11.0 billion yen -25.0 billion yen (Change from previous forecast -14.0 billion yen) Healthcare -0.2 billion yen -3.0 billion yen -7.0 billion yen (-4.0 billion yen) Medical equipment, medical IT Electronics - - - Business Innovation -1.1 billion yen -2.0 billion yen -4.0 billion yen (-2.0 billion yen) Multifunction devices, digital printers Imaging -2.4 billion yen -6.0 billion yen -14.0 billion yen (-8.0 billion yen) Instant photo systems , digital cameras Minimize the impact of rising prices through pricing measures and the procurement of alternative materials and components. 17 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices Reflecting the impact of recent increases in semiconductor memory and IT-related component prices, including PCs and servers, an additional ¥14.0 billion has been factored into the forecast compared with the previous outlook
Page 18
FUJIFILM Holdings Corporation Impact of the 2026 Kumamoto Earthquake Damage and Production Status • Employee safety was prioritized, the safety of all employees and their families was confirmed • No significant damage was confirmed at production facilities for display materials and semiconductor materials manufacturing sites in Kikuyo Town, Kumamoto Prefecture • Operations resumed gradually from August 2 following safety checks and equipment inspections Business and Financial Impact • Although delivery delays are expected for certain products, the overall impact on financial earnings is expected to be limited • No significant damage confirmed at Kumamoto manufacturing sites and operations gradually resumed • Financial impact expected to be limited 18 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices
Page 19
FUJIFILM Holdings Corporation 19 Appendices: Financial Results for Q1 FY2026 04 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices
Page 20
FUJIFILM Holdings Corporation Q1 | 3 Months Earnings 20 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) Q1 Healthcare 228.5 256.8 28.4 +12.4% 10.8 +4.7% Medical Systems 144.0 162.4 18.4 +12.8% 7.7 +5.4% Bio CDMO 54.2 57.7 3.5 +6.4% (2.0) (3.6%) LS Solutions 30.3 36.7 6.5 +21.4% 5.1 +16.7% Electronics 102.1 127.7 25.5 +25.0% 16.5 +16.2% Semiconductor Materials 64.7 84.9 20.2 +31.3% 12.6 +19.5% AF Materials 37.5 42.8 5.3 +14.1% 3.9 +10.3% Business Innovation 273.6 273.2 (0.3) (0.1%) (14.1) (5.2%) Business Solutions 75.8 77.8 2.0 +2.7% (1.5) (1.9%) Office Solutions 120.0 114.5 (5.5) (4.6%) (10.2) (8.5%) Graphic Communications 77.8 81.0 3.2 +4.1% (2.5) (3.2%) Imaging 145.3 168.8 23.5 +16.2% 6.9 +4.8% Consumer Imaging 77.3 96.7 19.4 +25.1% 10.1 +13.1% Professional Imaging 68.0 72.1 4.1 +6.0% (3.2) (4.6%) Total 749.5 826.5 77.0 +10.3% 20.1 +2.7% Q1 Healthcare 4.3 (12.7) (17.0) Turned to loss (19.4) Turned to loss [1.9%] [(4.9%)] Electronics 22.5 31.1 8.6 +38.2% 5.2 +23.1% [22.1%] [24.4%] Business Innovation 15.6 (1.4) (17.0) Turned to loss (10.0) Turned to loss [5.7%] [(0.5%)] Imaging 41.8 43.4 1.6 +3.9% (1.7) (4.1%) [28.7%] [25.7%] Corporate Expenses & Eliminations (8.8) (9.2) (0.4) (0.3) Total 75.3 51.2 (24.1) (32.0%) (26.2) (34.8%) [10.0%] [6.2%] Operation*² Operating Income [Operating Margin] FY2025 FY2026 Change Revenue FY2025 FY2026 Change Constant-currency basis *¹ *¹ *² Excluding foreign exchange impacts, one- time costs, raw material costs and rising semiconductor memory prices *¹ Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business within the Healthcare segment to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation.
Page 21
FUJIFILM Holdings Corporation Quarterly Earnings * Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business within the Healthcare segment to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation. 21 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) FY2025 FY2026 228.5 270.7 266.1 333.6 256.8 Medical Systems 144.0 170.3 170.2 217.1 162.4 Bio CDMO 54.2 66.8 61.6 74.6 57.7 LS Solutions 30.3 33.7 34.4 41.9 36.7 Electronics 102.1 107.3 119.2 127.5 127.7 Semiconductor Materials 64.7 70.6 77.7 81.7 84.9 AF Materials 37.5 36.8 41.5 45.8 42.8 Business Innovation 273.6 298.6 277.8 324.8 273.2 Business Solutions 75.8 92.3 80.8 108.0 77.8 Office Solutions 120.0 121.2 115.7 125.9 114.5 Graphic Communications 77.8 85.2 81.4 90.9 81.0 Imaging 145.3 146.2 194.2 141.4 168.8 Consumer Imaging 77.3 85.3 123.0 82.2 96.7 Professional Imaging 68.0 60.9 71.2 59.1 72.1 749.5 822.9 857.4 927.3 826.5 FY2025 FY2026 4.3 19.4 10.3 29.7 (12.7) Electronics 22.5 19.4 28.2 30.7 31.1 Business Innovation 15.6 15.8 5.4 27.0 (1.4) Imaging 41.8 38.6 55.1 24.5 43.4 (8.8) (10.0) (9.1) (10.0) (9.2) 75.3 83.2 90.0 101.8 51.2 Exchange Rates ￥/US$ ¥145 ¥148 ¥154 ¥157 ¥159 ￥/€ ¥164 ¥172 ¥179 ¥184 ¥185 Q1 Healthcare Total Revenue Q1 Q2 Q3 Q4 Total Operating Income Q1 Q2 Q3 Healthcare Corporate Expenses & Eliminations Q4 Q1 * *
Page 22
FUJIFILM Holdings Corporation Consolidated Revenue by Geographical Area 22 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) Ratio (%) Ratio (%) 34.3% 256.9 30.7% 253.7 (3.1) (1.2%) 20.7% 155.3 21.2% 175.3 19.9 +12.8% 16.6% 124.6 18.0% 148.4 23.9 +19.2% China 15.5% 116.5 16.6% 136.9 20.4 +17.5% Asia and others 28.4% 212.7 30.1% 249.1 36.3 +17.1% Overseas 65.7% 492.6 69.3% 572.8 80.2 +16.3% 100.0% 749.5 100.0% 826.5 77.0 +10.3% FY2026 Q1 Change Europe Consolidated total Japan The Americas FY2025 Q1
Page 23
FUJIFILM Holdings Corporation Operating Income Analysis (Q1 YoY) 23 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) Q1 FY2025 Actual FY2026 Actual Operation and others FX Raw Material price Memory price （b-a) One-time cost (a) FY2025 Q1 (b) FY2026 Q1 Business Detail Healthcare 4.3 (12.7) (17.0) (19.4) 1.2 (7.7) (0.2) 9.2 (8.5) 0.7 8.5 (8.5) - CDMO ｜Scheduled maintenance at Denmark facilities 0.7 - 0.7 Common ｜Sale of non-core assets / Others Electronics 22.5 31.1 8.6 5.2 3.8 (0.4) - - - - (0.2) - (0.2) AF ｜Structure strengthening expenses/ Others 0.2 - 0.2 Common ｜Sale of non-core assets / Others Business Innovation 15.6 (1.4) (17.0) (10.0) 0.7 (2.8) (1.1) (3.8) (0.4) (4.2) (1.3) (0.1) (1.4) Graphic ｜Structure strengthening expenses/ Others (1.7) (0.3) (2.0) Graphic ｜Disputed cost / Others (1.0) - (1.0) Offfice Solutions and Others ｜Structure strengthening expenses/ Others 0.2 - 0.2 Offfice Solutions and Others ｜Sale of non-core assets / Others Imaging 41.8 43.4 1.6 (1.7) 10.6 (2.6) (2.4) (2.3) - (2.3) (2.5) - (2.5) Common ｜Structure strengthening expenses / Others 0.2 - 0.2 Common ｜Sale of non-core assets / Others (8.8) (9.2) (0.4) (0.3) - - - - - - Total 75.3 51.2 (24.1) (26.2) 16.3 (13.5) (3.7) 3.1 (8.9) (5.8) Exchange Rates USD ¥145 ¥159 ¥14 Silver (10.9) EUR ¥164 ¥185 ¥21 Aluminum (2.9) Others (fuel etc) 0.2 Change Corporate Expenses & Eliminations
Page 24
FUJIFILM Holdings Corporation 24 Bio CDMO Business: Financial Results Trend Large-scale facilities Small- to medium- scale facilities * Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation. Small- to medium-scale (-) Unplanned shutdowns for regulatory inspections (-) Rebound from cancellation fees recognized in the previous fiscal year Large-scale (+) Expanded operations of new facilities (+) Rebound from scheduled maintenance in the previous fiscal year Revenue (billions of yen) EBITDA margin (including one-time costs) Revenue (billions of yen) EBITDA margin (including one-time costs) 1Q actual Annual forecast Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices FY25Q1 FY26Q1 54.2 57.7 +6% FY25 FY26 Previous Forecast FY26 Latest Forecast 257.2 300.0 280.0 +9% High single-digit % Negative single-digit % Negative single-digit % Negative double-digit % Breakeven Negative double-digit % Large-scale Small- to medium Scale Overall Approx.20% Mid-teens % Negative double-digit % Negative double-digit % Low single digit% Mid- single-digit % Large-scale Small- to medium Scale Overall Low-teens % Negative double-digit % Negative single-digit %
Page 25
FUJIFILM Holdings Corporation 25 Initiatives to Strengthen the Bio CDMO Business Although negotiations are progressing steadily, mainly for commercial products, challenges remain in accelerating the ramp-up of the new U.S. site, responding to regulatory inspections, and strengthening capabilities to support early- stage projects. Initiatives are underway to enhance operational capabilities and improve profitability FY26/1Q results and status Business enhancement initiatives Large- scale Small- to medium- scale Slower-than-expected launch of the new U.S. site Discussions with regulatory authorities aiming for early resumption of operations Strengthen operational capabilities at small- to medium-scale facilities Business and customer development: Launch of new management team at FUJIFILM Biotechnologies Operation enhancements: Improve service competitiveness by shortening process development lead times Advanced modalities: Addressing ADCs, bispecifics and others Implementation of proprietary technologies: Continuous manufacturing (secured new orders in July at the new U.K. facility) DX/AI deployment Increase the number of orders for short lead-time projects by accelerating technology transfer Unplanned shutdowns for regulatory inspections Low number of contracts for early-stage projects, as well as delayed manufacturing and earnings contributions from certain commercial products Projects are progressing steadily in both Denmark and the U.S. (1Q: Secured approx. $100M in orders) With the addition of the new facility in U.K. site, increasing number of negotiations including commercial products (1Q: Secured approx. $350M in orders) Increase production volume by accelerating manufacturing cycles Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices
Page 26
FUJIFILM Holdings Corporation Full-year Forecast for FY2026 Revenue by Business * Business related to process development and contract manufacturing of cell therapy using iPS cells have been reclassified from the LS Solutions business within the Healthcare segment to the Bio CDMO business. The information for FY2025 has been restated in line with the above change in the segmentation. 26 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) FY2026 Previous forecast (May12, 2026) Amount of money With currency impact Without currency impact Amount of money With currency impact Without currency impact Healthcare 1,098.9 1,170.0 1,180.0 81.1 +7.4% +5.1% 10.0 +0.9% (1.8%) Medical Systems 701.6 720.0 750.0 48.4 +6.9% 30.0 +4.2% Bio CDMO 257.2 300.0 280.0 22.8 +8.9% (20.0) (6.7%) LS Solutions 140.2 150.0 150.0 9.8 +7.0% - - Electronics 456.2 475.0 510.0 53.8 +11.8% +9.0% 35.0 +7.4% +4.4% Semiconductor Materials 294.6 310.0 335.0 40.4 +13.7% 25.0 +8.1% AF Materials 161.6 165.0 175.0 13.4 +8.3% 10.0 +6.1% Business Innovation 1,174.8 1,175.0 1,200.0 25.2 +2.1% (0.2%) 25.0 +2.1% (0.3%) Business Solutions 356.8 380.0 390.0 33.2 +9.3% 10.0 +2.6% Office Solutions 482.7 480.0 480.0 (2.7) (0.6%) - - Graphic Communications 335.3 315.0 330.0 (5.3) (1.6%) 15.0 +4.8% Imaging 627.1 650.0 670.0 42.9 +6.8% +2.2% 20.0 +3.1% (1.7%) Consumer Imaging 367.9 375.0 390.0 22.1 +6.0% 15.0 +4.0% Professional Imaging 259.2 275.0 280.0 20.8 +8.0% 5.0 +1.8% Total 3,357.0 3,470.0 3,560.0 203.0 +6.0% +3.2% 90.0 +2.6% (0.4%) Exchange Rates ￥/US$ ¥151 ¥150 ¥156 ¥5 ¥6 ￥/€ ¥175 ¥175 ¥181 ¥6 ¥6 FY2025 Actual FY2026 Revised forecast (Aug.6,2026) Change from previous year Change from previous forecast * *
Page 27
FUJIFILM Holdings Corporation Operating Income Analysis (FY2026 Forecast vs. Previous Forecast) 27 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) Operation FX Raw Material price Memory price （b-a) One-time cost (a) Previous forecast (b) Revised forecast Business Detail Healthcare 69.0 41.0 (28.0) (30.0) 5.0 0.5 (4.0) 0.5 6.0 6.5 0.5 6.0 6.5 Common ｜Sale of non-core assets / Others Electronics 106.0 120.0 14.0 8.5 6.0 (0.5) - - 0.5 0.5 - (1.0) (1.0) AF ｜Structure strengthening expenses/ Others - 1.5 1.5 Common ｜Sale of non-core assets / Others Business Innovation 65.0 80.0 15.0 3.5 3.0 (4.5) (2.0) 15.0 (7.0) 8.0 (0.5) (11.0) (11.5) Graphic ｜Structure strengthening expenses/ Others (1.0) (2.5) (3.5) Graphic ｜Disputed cost / Others 1.5 (9.5) (8.0) Office Solutions and Others ｜Structure strengthening expenses/ Others 15.0 16.0 31.0 Office Solutions and Others ｜Sale of non-core assets / Others Imaging 162.0 162.0 - (4.0) 12.0 - (8.0) - (1.5) (1.5) - (5.0) (5.0) Common ｜Structure strengthening expenses/ Others - 3.5 3.5 Common ｜Sale of non-core assets / Others (37.0) (38.0) (1.0) (1.0) - - - - - - Total 365.0 365.0 - (23.0) 26.0 (4.5) (14.0) 15.5 (2.0) 13.5 Exchange Rates USD ¥150 ¥156 ¥6 Silver 1.0 EUR ¥175 ¥181 ¥6 Aluminum (4.0) Others (fuel etc) (1.5) Change Corporate Expenses & Eliminations Previous forecast (May12, 2026) Revised forecast (Aug.6,2026)
Page 28
FUJIFILM Holdings Corporation Consolidated Balance Sheets Q1 FY2026 (April to June 2026) 28 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices Mar. 2025 Mar. 2026 Jun. 2026 Change from Mar. 2026 Mar. 2025 Mar. 2026 Jun. 2026 Change from Mar. 2026 Cash and cash equivalents 172.1 170.6 150.7 (19.9) Short-term and long-term debt 685.9 894.9 975.6 80.7 Notes and accounts receivable 700.0 762.5 706.5 (56.0) Notes and accounts payable 390.6 389.8 398.5 8.6 Inventories 544.0 600.8 667.1 66.3 Other liabilities 820.7 924.7 889.7 (35.0) Other current assets 165.6 185.2 195.6 10.4 Total liabilities 1,897.2 2,209.4 2,263.8 54.4 Total current assets 1,581.7 1,719.0 1,719.8 0.7 Total FUJIFILM Holdings shareholders' equity 3,348.5 3,839.6 3,898.5 58.9 Property, plant and equipment 1,786.5 2,308.3 2,396.9 88.6 Noncontrolling interests 4.2 4.8 5.1 0.2 Goodwill, net 947.9 997.1 1,006.3 9.2 Total equity 3,352.7 3,844.4 3,903.5 59.2 Other noncurrent assets 933.8 1,029.3 1,044.3 15.0 Total liabilities and equity 5,249.9 6,053.8 6,167.3 113.5 Total noncurrent assets 3,668.2 4,334.7 4,447.5 112.8 (yen) Total assets 5,249.9 6,053.8 6,167.3 113.5 Exchange Rates Mar. 2025 Mar. 2026 Jun. 2026 Change from Mar. 2026 ￥/US$ ¥150 ¥160 ¥162 ¥2 ￥/€ ¥162 ¥183 ¥185 ¥2 (Billions of yen)
Page 29
FUJIFILM Holdings Corporation Capital expenditure (Property, plant and equipment) Capital expenditure (Software, rental equipment, etc.) Depreciation & Amortization Capital Expenditure and Depreciation & Amortization (Billions of yen) 29 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices (Billions of yen) Healthcare 105.3 78.2 426.3 230.0 Electronics 4.4 5.8 36.9 52.0 Business Innovation 4.4 5.0 25.4 29.0 Imaging 2.1 3.4 16.6 23.0 Corporate 0.4 1.6 1.8 4.0 Capex (Tangible fixed assets) 116.6 94.0 506.9 338.0 Healthcare 3.8 4.7 18.4 18.0 Electronics 0.6 0.1 1.6 2.0 Business Innovation 8.0 8.0 38.4 24.0 Imaging 0.9 3.8 12.4 15.0 Corporate 0.6 0.6 4.1 7.0 Capex (Software, rental equipment and others） 13.8 17.2 75.0 66.0 Healthcare 17.2 24.0 74.5 101.0 Electronics 7.3 7.7 30.7 34.0 Business Innovation 11.5 12.7 45.8 50.0 Imaging 3.7 4.8 17.2 21.0 Corporate 1.1 1.2 4.3 4.0 Depreciation & Amortization 40.9 50.4 172.4 210.0 Q1 Full Year FY2025 FY2026 FY2025 FY2026 Forecast532.1 506.9 338.0 75.0 75.0 66.0 163.6 172.4 210.0 0.0 200.0 400.0 600.0 25/3 Actual 26/3 Actual 27/3 Forecast 25/3 Actual 26/3 Actual 27/3 Forecast 25/3 Actual 26/3 Actual 27/3 Forecast Capital Expenditure and Depreciation & Amortization
Page 30
FUJIFILM Holdings Corporation R&D Expenses SG&A Expenses R&D Expenses and SG&A Expenses (Billions of yen) Ratio to revenue 30 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices FY2025 FY2026 FY2025 FY2026 Forecast Healthcare 14.8 13.8 53.3 Electronics 7.0 8.1 28.2 Business Innovation 14.0 15.0 55.4 Imaging 3.0 4.3 13.4 Corporate 1.9 1.2 7.5 R&D Expenses 40.6 42.3 157.8 172.0 5.4% 5.1% 4.7% 4.8% SG&A Expenses 196.6 229.9 861.5 26.2% 27.8% 25.7% Full Year <Ratio to revenue> (Billions of yen) Q1 <Ratio to revenue>163.4 157.8 172.0 806.5 861.5 5.1% 4.7％ 5.0% 25.2% 25.7% 0.0% 10.0% 20.0% 30.0% 40.0% 0.0 300.0 600.0 900.0 25/3 Actual 26/3 Actual 27/3 Forecast 25/3 Actual 26/3 Actual R&D Expenses and SG&A Expenses
Page 31
FUJIFILM Holdings Corporation Mar.2025 June 2025 Sep.2025 Dec.2025 Mar.2026 June 2026 Consolidated total 72,593 74,534 74,205 73,975 73,526 74,156 ▐ Exchange rates (average) / Raw material prices (average) ▐ Exchange rate sensitivity: Impact of 1 yen change (full year) ▐ Number of employees Market Trend and Number of Employees Last updated: Apr. 17, 2024 31 Earnings Highlights Q1 FY2026 FY2026 Forecast Appendices Revenue Operating Income US＄ per 1 yen +5.0 billion yen +1.0 billion yen € per 1 yen +1.5 billion yen +0.8 billion yen FY2025 FY2026 Unit 1Q 2Q 3Q 4Q Full Year 1Q 2-4Q Full Year US＄ ¥/＄ 145 148 154 157 151 159 155 156 € ¥/€ 164 172 179 184 175 185 180 181 Silver 1,000 yen/kg 155 184 249 440 247 383 400 395
Page 32
FUJIFILM Holdings Corporation 32 References ▍ FUJIFILM Holdings - Investor Relations https://ir.fujifilm.com/en/investors.html ▍ FUJIFILM Holdings Integrated Report https://ir.fujifilm.com/en/investors/ir-materials/integrated-report.html ▍ IR Materials https://ir.fujifilm.com/en/investors/ir-materials.html ▍ Business Activities of the Fujifilm Group https://ir.fujifilm.com/en/investors/ir-materials/business-overview.html Earnings Highlights Q3 FY2025 FY2025 Forecast Appendices
Page 33
FUJIFILM Holdings Corporation